MDA 2022 symposium: Throughout the disease continuum: Corticosteroid treatment in Duchenne muscular dystrophy
Watch our hybrid Industry Forum at MDA 2022, which discusses the latest clinical findings on the role of corticosteroid treatment in the management of Duchenne muscular dystrophy (DMD)
Learn about the importance of delaying markers of DMD disease progression throughout the continuum of the condition
Understand the importance of early and continuous corticosteroid use for slowing disease progression
Review the latest clinical trial and real-world data for the use of corticosteroids in patients with DMD
This is a hybrid Industry Forum hosted by PTC Therapeutics at MDA 2022 and was organized and funded by PTC Therapeutics.
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at firstname.lastname@example.org. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This is a recording of our live webinar. This webinar recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200062 I March 2022
Sign in or register to access exclusive content on this site